CDXC (POTENTIAL BUY LEVEL) ***BULLISH SENTIMENT This is just my basic MONTHLY charting.
I have marked what I see as the POSSIBLE bottom (support).
I see overall DOWNTREND with possible reversal.
I have marked my potential BUY LEVELS for LONGS//CALLS.
CDXC
CDXC running towards 10 with impressive volumesAs one of few micro-cap with real revenues (40% growth) blessed with huge market potential and very competent managment, I suspect the company will be bought out by one of the SPACs with too much cash but no real business. Patience is likely to be rewarded handsomely.
Volumes have been tripling for days, a prelude to some excitement to come?
CDXC: Small Float Biopharma with BIG Potential $20After basing for many years, CDXC is showing signs of awakening. Stocks are being accumulated but not aggressively. It's one of few bio stocks with insider buying at the current price.
The co is likely on track doing $200 mil revenue in 2 or 3 years, 10X of the 200 mil revenue = 2 bil market cap, with about 62 mil shares O/S. Potentially huge valuation creation. Backed by smart biopharma investors with a tiny float (56% controlled by 20 investors). Their product is patented with an 80% gross margin.
It is however a stock for patient investors, not fly by the night type of stocks. It is in my Long Term portfolio.
CDXC 4.8: Small Float Biotech backed by Li Ka Shing In this market where SPEC trades at billions with NO revenue, I like CDXC though I may be early. Yes it's not TSLA, yes Value does not work in this market but
With a tiny market cap of 290 mil and revenue growth at 40% (still early-stage market), I am betting with Li Ka Shing, one of the richest and other top 20 institutions including Blackrock who collectively owns 55% of the stock. Short interest is small at 7%.
The better story is that the stock has been basing for a long time, and technicals are improving. I don't want to wait for breakout then buy as by then I would be paying too much a premium. So good enough for me with the IMPROVING technicals and a largely positive trend, and a real growth story.
investors.chromadex.com
asia.nikkei.com
Top Shareholders
Top 25 shareholders own 54.62% of the company
Ownership Name Shares Current Value Change % Portfolio %
10.49%
Ka-shing Li 6,500,937 $31.4m 0% no data
10.29%
Hoi Shuen Chau 6,377,783 $30.8m 0% no data
4.53%
BlackRock, Inc. 2,804,544 $13.5m -0.81% no data
3.97%
The Vanguard Group, Inc. 2,461,485 $11.9m 9.03% no data
3.8%
Li Ka Shing (Global) Foundation, Endowment Arm 2,353,139 $11.4m 0% 3.25%
3.11%
Phillip and Patricia Frost Philanthropic Foundation, Inc, Endowment Arm 1,929,542 $9.3m 0% 42.91%
2.76%
